Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 09:10 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on...
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
August 20, 2024 09:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on...
Actuate Therapeutics Announces Closing of Initial Public Offering
August 14, 2024 16:05 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies...
Actuate Therapeutics Announces Pricing of Initial Public Offering
August 12, 2024 20:27 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies...
Actuate Therapeutics Files Registration Statement for Initial Public Offering
May 28, 2024 07:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (“Actuate”) announced today that it has filed a registration statement with the Securities and Exchange...
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
April 08, 2024 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from...
Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer
August 01, 2023 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug...
Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting
May 30, 2023 08:00 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific...
UPDATE -- Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
April 10, 2023 10:22 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from...
Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting
April 10, 2023 07:59 ET
|
Actuate Therapeutics
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from...